For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ FOXO4-DRI
Illustration for FOXO4-DRI

THE PEPSRADAR ENCYCLOPEDIA

FOXO4-DRI

Senescent-cell biology

Research topics · Sources checked 2026-10-04

Read the studies ↓

FOXO4-DRI · KEY FACTS

Content updated · how dates work

Saved peptides

What is FOXO4-DRI?

FOXO4-DRI is an experimental peptide designed to disrupt an interaction involved in senescent-cell survival. Its widely discussed aging findings come from cell and mouse experiments.

Biological role or research focus

Senescent-cell biology.

Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.

Role reference: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

Names you may encounter

FOXO4 D-retro-inverso peptide

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Experimental D-retro-inverso senolytic peptide
Research focus
Senescent-cell biology
Featured evidence
Animal and cell study
Source check
October 4, 2026

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

Quick answers

Is FOXO4-DRI FDA approved?
No. No FDA-approved drug contains FOXO4-DRI. Source ↗
Is FOXO4-DRI safe?
FOXO4-DRI is an experimental senolytic peptide studied only in cells and animals. There are no human safety data, and in one mouse study senolytics worsened lung blood-vessel disease. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is FOXO4-DRI banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Animal / mixed laboratory research
StudyTypePopulation / model
FOXO4–p53 interference in senescent cells (2017)Animal and cell studySenescent cells and naturally aged or accelerated-aging mice.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Animal and cell study · 2017

FOXO4–p53 interference in senescent cells

What did this publication test, and what did it find?

Population / model
Senescent cells and naturally aged or accelerated-aging mice.
Study design
Mechanistic cell experiments and mouse interventions assessing senescence-associated changes and physical or organ-function measures.
Main finding
The study reported senescent-cell apoptosis and improvements in selected mouse measures, including fitness, fur density, and kidney function.
Limits & context
Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming FOXO4-DRI as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. ↗
Circulation · 2023 Feb 21 · Journal Article, Research Support, Non-U.S. Gov't

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. ↗
Nature communications · 2025 Jul 1 · Journal Article
Read available full text ↗

FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. ↗
Communications biology · 2025 Feb 24 · Journal Article
Read available full text ↗

FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. ↗
Frontiers in bioengineering and biotechnology · 2025 · Journal Article
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

FOXO4-DRI is an experimental senolytic peptide studied only in cells and animals. There are no human safety data, and in one mouse study senolytics worsened lung blood-vessel disease.

Human safety data: None

No published human safety studies were found. Clearing senescent cells can affect tissues differently, and current evidence comes only from mouse and cell experiments.

Unassessed: no human safety data

Warning signs in animal or lab studies: Heart or blood pressure problems

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Harms seen in animal or lab studies

  • In mouse models, clearing senescent cells with FOXO4-DRI or another senolytic worsened pulmonary hypertension measures

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FOXO4-p53 interference in senescent cells (Cell, 2017) ↗ · Eliminating senescent cells can promote pulmonary hypertension (2023) ↗

Safety & what remains unknown

Eliminating senescent cells can affect tissues differently. This preclinical report cannot define a human risk profile or verify a supplier’s material.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

Evidence boundaries

Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

The featured publication examines senescence and aging models, including chemotherapy-associated injury. It is not a human longevity or rejuvenation trial.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

The investigators targeted the FOXO4–p53 interaction to favor apoptosis in senescent cells. Selectivity observed in experimental systems does not establish selective clearance or safety in a person.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

Questions worth asking

  • Has this study proved human rejuvenation?
  • What material, population, and route were actually studied?
  • Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Has this study proved human rejuvenation?

No. Its cell and mouse results support a research hypothesis; they do not demonstrate a human longevity benefit.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections